NASDAQ · MLYS
Healthcare · Biotechnology
$15.52
Down-$0.29 (-1.83%)
Updated Nov 11, 2026, 4:06 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MLYS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 10, 2026
MLYS closed at $15.52 after 21 trading sessions, down 26.10% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 10, 2026 | $15.48 | $16.52 | $15.05 | $15.52 | 1.72M |
| Nov 9, 2026 | $15.92 | $16.40 | $15.20 | $15.81 | 2.96M |
| Nov 6, 2026 | $15.23 | $15.645 | $14.91 | $15.33 | 1.34M |
| Nov 5, 2026 | $17.66 | $17.66 | $15.15 | $15.24 | 2.55M |
| Nov 4, 2026 | $16.41 | $17.02 | $15.53 | $17.00 | 1.93M |
| Nov 3, 2026 | $15.69 | $16.25 | $15.33 | $15.99 | 2.61M |
| Nov 2, 2026 | $18.27 | $18.285 | $15.42 | $15.55 | 4.59M |
| Oct 30, 2026 | $20.99 | $20.99 | $18.11 | $18.18 | 3.98M |
| Oct 29, 2026 | $21.64 | $22.48 | $21.105 | $21.24 | 2.08M |
| Oct 28, 2026 | $21.13 | $22.145 | $20.9183 | $21.38 | 1.54M |
| Oct 27, 2026 | $20.59 | $21.235 | $20.18 | $21.13 | 3.2M |
| Oct 26, 2026 | $20.71 | $20.71 | $20.25 | $20.56 | 795.99K |
| Oct 23, 2026 | $21.38 | $21.38 | $20.32 | $20.55 | 1.09M |
| Oct 22, 2026 | $21.00 | $21.60 | $20.70 | $21.47 | 824.73K |
| Oct 21, 2026 | $21.90 | $22.24 | $21.10 | $21.10 | 808.55K |
| Oct 20, 2026 | $20.87 | $21.76 | $20.58 | $21.58 | 1M |
| Oct 19, 2026 | $20.57 | $21.11 | $20.27 | $20.92 | 1.12M |
| Oct 16, 2026 | $21.60 | $21.60 | $20.12 | $20.30 | 1.18M |
| Oct 15, 2026 | $21.04 | $21.83 | $20.825 | $21.64 | 1.09M |
| Oct 14, 2026 | $20.74 | $22.2337 | $20.61 | $20.76 | 1.16M |
| Oct 13, 2026 | $22.04 | $22.815 | $20.41 | $21.00 | 3.35M |
The latest Smart Investors Daily articles mentioning MLYS.
Company
Market Activity
Research & News
MLYS research
Company profile and research snapshot.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | UBS | Neutral | — |
| Oct 12, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 27, 2026 | TD Cowen | Buy | — |
| Mar 13, 2026 | B of A Securities | Buy | — |
| Dec 19, 2025 | Stifel | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 9, 2026
Investing.com -- Mineralys Therapeutics Inc (NASDAQ:MLYS) shares rose 4.7% in Monday trade after the company reported long-term results from its Transform-HTN trial showing lorundrostat demonstrated sustained blood pressure reductions in patients with uncontrolled or resistant hypertension.
Yahoo · Nov 8, 2026
– In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure (AOSBP) of 17.8 mmHg at Week 48 from Launch-HTN baseline – – 56% of participants reached AOSBP below 130 mmHg at Week 48 – – Long-term treatment with lorundrostat was well tolerated, with no new clinically relevant safety findings beyond Launch-HTN – – U.S. FDA review of lorundrostat is underway, with a PDUFA target
Yahoo · Nov 6, 2026
RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on November 3, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award coveri
SeekingAlpha · Nov 5, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MLYS.
